10X Genomics Inc. Reports Strong Q2 2026 Financial Performance
10X Genomics Inc. (NASDAQ: TXG) released its second‑quarter 2026 financial results on August 6, 2026. The company reported revenue of $151.0 million, up 3 % from the same period in 2025 when non‑recurring settlement revenue is excluded. After subtracting a $1.6 million patent‑litigation settlement, revenue for the quarter was $149.4 million.
Earnings and Guidance
- GAAP earnings per share (EPS): –$0.14, outperforming analysts’ expectations by $0.11.
- Revenue: $151 million, surpassing the consensus estimate by $4.39 million.
The company’s price‑earnings ratio remains negative at –265.42, reflecting its continued investment in research and expansion of its product portfolio.
Strategic Acquisitions and Partnerships
During the quarter, 10X Genomics acquired Proteintech Genomics, a division of Proteintech Group. The acquisition strengthens the company’s multiomics capabilities by adding advanced protein detection technologies to its existing single‑cell and spatial platforms.
The company also announced multi‑year research collaborations with Cleveland Clinic and Lausanne University Hospital. These partnerships focus on advancing diagnostic applications of single‑cell and spatial technologies for cancer care, thereby reinforcing 10X Genomics’ diagnostics strategy.
Product Highlights
A key driver of the quarter’s performance was the strong customer response to the Atera platform. 10X Genomics noted significant engagement across the research ecosystem, indicating robust demand for its high‑throughput, multi‑omics solutions.
Market Context
The multiomics market is projected to grow from $3.18 billion in 2026 to $5.70 billion by 2031, according to MarketsandMarkets, at a CAGR of 12.3 %. North America is the largest market, accounting for 44.2 % of the global share in 2025. This expansion underscores the increasing adoption of integrated biological data analysis across drug discovery, biomarker identification, and clinical research.
Market Reaction
Following the earnings announcement, 10X Genomics’ stock closed at $47.46 on August 4, 2026, within a 52‑week range of $11.16 to $50.34. The company’s market capitalization stands at $6 billion.
The broader market experienced mixed movements; while major indices posted new highs, the Nasdaq was down approximately 0.4 % on the day, reflecting a cautious environment ahead of the July payroll report and ongoing volatility in the U.S. dollar and commodity markets.
Conclusion
10X Genomics’ Q2 2026 results demonstrate continued revenue growth, improved earnings performance relative to expectations, and strategic progress in expanding its multiomics platform. The company’s recent acquisition and research collaborations position it well to capitalize on the projected expansion of the multiomics market in the coming years.
